|
|
Article: BioCryst Reports Lead Flu Drug Fails In Phase III Against Placebo.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Washington Editor
BioCryst Pharmaceuticals Inc. stopped development of its lead drug candidate, peramivir, on poor preliminary data from a Phase III influenza study.
The news sent the company's stock (NASDAQ:BCRX) downward to close at 91 cents Tuesday, falling $1.27, or 58.3 percent.
According to the company, early data from the Phase III influenza A and B trial did not demonstrate a statistically significant difference in the primary efficacy endpoint: the length of time from the first dose to the onset of clinically significant relief of influenza symptoms, between the drug and placebo groups (p=0.17).
"Obviously, we are not happy ...